Literature DB >> 21828197

Genetic variations within the OPA1 gene are not associated with neuromyelitis optica.

Kamil S Sitarz1, Patrick Yu-Wai-Man, Gavin Hudson, Anu Jacob, Mike Boggild, Rita Horvath, Patrick F Chinnery.   

Abstract

Neuromyelitis optica (NMO) is an idiopathic demyelinating disease which predominantly affects the optic nerve and spinal cord. Multiplex NMO pedigrees have been reported but the genetic risk factors conferring this increased familial susceptibility have not yet been determined. OPA1 mutations have recently been identified in families with progressive visual failure and spastic paraparesis, raising the possibility that OPA1 genetic variants could contribute to the aetiology of NMO. We therefore screened for OPA1 in 32 patients with NMO. No pathogenic mutations were found, and none of the 13 single-nucleotide polymorphisms identified were associated with an increased risk of developing NMO.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21828197      PMCID: PMC4040403          DOI: 10.1177/1352458511416838

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  9 in total

Review 1.  Does mitochondrial DNA predispose to neuromyelitis optica (Devic's disease)?

Authors:  Gavin Hudson; Catherine Mowbray; Joanna L Elson; Anu Jacob; Michael Boggild; Antonio Torroni; Patrick F Chinnery
Journal:  Brain       Date:  2007-10-29       Impact factor: 13.501

2.  Complexity and heterogeneity in demyelinating disease.

Authors:  Alastair Compston
Journal:  Brain       Date:  2007-05       Impact factor: 13.501

3.  Subclinical multisystem neurologic disease in "pure" OPA1 autosomal dominant optic atrophy.

Authors:  M R Baker; K M Fisher; R G Whittaker; P G Griffiths; P Yu-Wai-Man; P F Chinnery
Journal:  Neurology       Date:  2011-09-14       Impact factor: 9.910

Review 4.  Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies.

Authors:  Patrick Yu-Wai-Man; Philip G Griffiths; Patrick F Chinnery
Journal:  Prog Retin Eye Res       Date:  2010-11-26       Impact factor: 21.198

5.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

6.  Multi-system neurological disease is common in patients with OPA1 mutations.

Authors:  P Yu-Wai-Man; P G Griffiths; G S Gorman; C M Lourenco; A F Wright; M Auer-Grumbach; A Toscano; O Musumeci; M L Valentino; L Caporali; C Lamperti; C M Tallaksen; P Duffey; J Miller; R G Whittaker; M R Baker; M J Jackson; M P Clarke; B Dhillon; B Czermin; J D Stewart; G Hudson; P Reynier; D Bonneau; W Marques; G Lenaers; R McFarland; R W Taylor; D M Turnbull; M Votruba; M Zeviani; V Carelli; L A Bindoff; R Horvath; P Amati-Bonneau; P F Chinnery
Journal:  Brain       Date:  2010-02-15       Impact factor: 13.501

Review 7.  The spectrum of neuromyelitis optica.

Authors:  Dean M Wingerchuk; Vanda A Lennon; Claudia F Lucchinetti; Sean J Pittock; Brian G Weinshenker
Journal:  Lancet Neurol       Date:  2007-09       Impact factor: 44.182

8.  Neuromyelitis optica: effect of gender.

Authors:  Dean M Wingerchuk
Journal:  J Neurol Sci       Date:  2009-09-08       Impact factor: 3.181

9.  OPA1 increases the risk of normal but not high tension glaucoma.

Authors:  P Yu-Wai-Man; J D Stewart; G Hudson; R M Andrews; P G Griffiths; M K Birch; P F Chinnery
Journal:  J Med Genet       Date:  2009-07-05       Impact factor: 6.318

  9 in total
  1 in total

1.  No association between identified multiple sclerosis non-MHC risk loci and neuromyelitis optica.

Authors:  Qi-Bing Liu; Zhen-Xin Li; Gui-Xian Zhao; Hai Yu; Zhi-Ying Wu
Journal:  Neurosci Bull       Date:  2014-06-13       Impact factor: 5.203

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.